Related Experiment Video

Updated: Dec 3, 2025

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

87.1K

Neurodevelopmental outcomes after neonatal caffeine therapy

Anne Synnes1, Ruth E Grunau1

  • 1Division of Neonatology, British Columbia's Women's Hospital, Vancouver, BC, Canada; Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada; BC Children's Hospital Research Institute, Vancouver, BC, Canada.

Seminars in Fetal & Neonatal Medicine
|October 30, 2020
PubMed

Insights

Caffeine administration in premature infants improves survival without neurodevelopmental disability and shows long-term safety. Early, higher doses may offer benefits, but further research is needed.

Area of Science:

  • Neonatal neuroscience
  • Pharmacology
  • Developmental pediatrics

Background:

  • Adverse neurodevelopmental outcomes are a significant concern in premature infants.
  • The Caffeine for Apnea of Prematurity trial investigated long-term effects of caffeine.
  • Caffeine acts as an adenosine receptor antagonist with systemic effects.

Purpose of the Study:

  • To evaluate the long-term efficacy and safety of caffeine in improving neurodevelopmental outcomes for premature infants.
  • To explore potential mechanisms of caffeine's benefits, including neuroprotection and reduction of bronchopulmonary dysplasia.

Main Methods:

  • Analysis of data from the large international Caffeine for Apnea of Prematurity trial.
  • Assessment of outcomes at 18 months and long-term safety up to 11 years of age.

Main Results:

  • Caffeine administration was associated with improved survival without neurodevelopmental disability at 18 months.
  • Long-term safety of caffeine was demonstrated up to 11 years.
  • Caffeine's effects are dose- and age-dependent, with potential risks noted in animal studies regarding hypoxia.

Conclusions:

  • Caffeine is a beneficial intervention for premature infants, improving survival and neurodevelopmental outcomes.
  • While generally safe, the optimal dosing strategy requires further investigation, considering potential risks.
  • Early and higher-dose caffeine administration may enhance benefits, warranting continued research.

Keywords:
CaffeineChild development disordersInfantMethylxanthinesNeuroprotectionPremature

More Related Videos

Experimental Protocol for Examining Behavioral Response Profiles in Larval Fish: Application to the Neuro-stimulant Caffeine08:33

Experimental Protocol for Examining Behavioral Response Profiles in Larval Fish: Application to the Neuro-stimulant Caffeine

Published on: July 24, 2018

11.5K
Continuous Video Electroencephalogram during Hypoxia-Ischemia in Neonatal Mice09:29

Continuous Video Electroencephalogram during Hypoxia-Ischemia in Neonatal Mice

Published on: June 11, 2020

3.6K

Related Concept Videos

Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
589
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.8K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
101